{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-011767","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2025-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.816972+00:00","generated_at":"2026-05-23T23:14:55.244121+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AngioDynamics raises FY2025 guidance after Q3; Med Tech sales up 22% YoY","bullets":["Pro forma Q3 net sales $72.0M (+9.2% YoY); Med Tech $31.3M (+22.2%) driven by Auryon, AngioVac, AlphaVac, NanoKnife.","GAAP net loss $4.4M ($0.11 loss per share); adjusted loss $0.08 per share; adjusted EBITDA $1.3M vs -$3.6M a year ago.","FY2025 guidance raised: net sales $285-288M, Med Tech growth 14-16%, gross margin 53-54%, adjusted EBITDA $4-5M, adjusted EPS loss $(0.31)-(0.34).","Received FDA 510(k) clearance for NanoKnife System for prostate tissue ablation; initiated AMBITION BTK RCT for Auryon.","Secured $25M revolver commitment from J.P. Morgan for working capital flexibility; expects positive operating cash flow in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-011767","json":"https://secwatch.observer/filing/0001140361-25-011767.json","markdown":"https://secwatch.observer/filing/0001140361-25-011767.md","text":"https://secwatch.observer/filing/0001140361-25-011767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125011767/0001140361-25-011767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125011767/ef20046769_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T23:14:55.244121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}